Publications by authors named "Zuzana Zdeblova Cermakova"
Article Synopsis
- * A cohort of 55 patients was followed for a median of nearly 20 months, revealing an overall survival rate of about 61.8% and a disease-specific survival rate of 72.7%, with significant correlations found between high PD-L1 expression and better survival outcomes.
- * The findings suggest that combining high PD-L1 expression with either increased CD8+ TIL counts or higher TIL density could serve as a strong prognostic factor for patient outcomes, indicating
Introduction: The incidence of advanced oral cavity and oropharyngeal cancers is generally high. Treatment outcomes for patients, especially those unfit for comprehensive cancer treatment, are unsatisfactory. Therefore, the search for factors to predict response to treatment and increase overall survival is underway.
View Article and Find Full Text PDFPurpose: We evaluated the efficiency and toxicity of stereotactic hypofractionated boost in combination with conventionally fractionated radiotherapy in the treatment of advanced floor of the mouth cancer.
Methods: Thirty-seven patients with advanced stage of the floor of the mouth cancer, histologically confirmed squamous cell carcinoma (p16 negative) ineligible for surgical treatment, were indicated for radiochemotherapy or hyperfractionated accelerated radiotherapy (HART). The radiotherapy protocol combined external beam radiotherapy (EBRT) and a stereotactic hypofractionated boost to the primary tumor.